ストックスクリーナーアプリを入手
1.11
6.72%
-0.08
アフターアワーズ：
1.16
0.05
+4.50%
前日終値:
$1.19
開ける：
$1.21
24時間の取引高:
495.97K
Relative Volume:
0.51
時価総額：
$71.66M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-0.6033
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
-9.02%
1か月 パフォーマンス:
-26.00%
6か月 パフォーマンス:
-67.73%
1年 パフォーマンス:
-83.16%
1日の値動き範囲:
$1.105
$1.22
1週間の範囲:
$1.105
$1.325
52週間の値動き範囲:
$1.105
$6.79
Pyxis Oncology Inc Stock (PYXS) Company Profile
PYXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.11 | 71.66M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan
Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire
Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St
Pyxis Oncology rises on FDA fast track tag for lead asset - MSN
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com
FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada
Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq
PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan
FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India
Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq
Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance
Pyxis Oncology Inc [PYXS] Investment Appeal on the Rise - Knox Daily
Nothing is Better Than Pyxis Oncology Inc (PYXS) stock at the moment - SETE News
Pyxis Oncology Inc [PYXS] Investment Guide: What You Need to Know - Knox Daily
Financial Health Report: Pyxis Oncology Inc (PYXS)’s Ratios Tell a Tale - The Dwinnex
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts - Armenian Reporter
Pyxis Oncology Inc (PYXS) Beta Value: Understanding the Market Risk - The News Heater
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
A year in review: Pyxis Oncology Inc (PYXS)’s performance in the last year - US Post News
Financial Metrics Unveiled: Pyxis Oncology Inc (PYXS)’s Key Ratios in the Spotlight - The Dwinnex
BlackRock, Inc. Increases Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology Initiates New Combination Trial For PYX-201 And Expands Monotherapy Cohorts - Nasdaq
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Marketscreener.com
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of ... - The Bakersfield Californian
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):